Head & neck · 2026
A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD-1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fiedler Mathias, Baumann Lea, Eichberger Jonas, Gottsauner Maximilian, Schuderer Johannes G, Schulz Daniela, Meier Johannes K, Bauer Richard J, Poeck Hendrik, Grube Matthias, Gerken Michael, Reichert Torsten E, Weber Florian, Ettl Tobias
Аннотация
BACKGROUND: Predictive biomarkers for response to PD-1 blockade in recurrent or metastatic HNSCC remain limited. We investigated whether coordinated expression of multiple inhibitory immune checkpoints defines a clinically relevant biomarker phenotype.
METHODS: Clinical and immunohistochemical data from 78 patients with recurrent or metastatic HNSCC treated with nivolumab or pembrolizumab were retrospectively analyzed. Expression of PD-L1, LAG-3, TIM-3, and IDO1 on tumor-infiltrating immune cells was assessed. A composite immune checkpoint phenotype was defined by concurrent immune-cell expression of these markers. Associations with treatment response and survival were analyzed.
RESULTS: The composite immune checkpoint phenotype was observed in 10.1% of tumors and was strongly associated with objective response (p < 0.001), disease control (p = 0.006), and improved overall, disease-specific, and progression-free survival (all p ≤ 0.030). In multivariable analysis, this phenotype independently predicted overall (p = 0.031) and disease-specific survival (p = 0.011).
CONCLUSION: Coordinated expression of multiple inhibitory immune checkpoints identifies an inflamed tumor microenvironment associated with improved outcomes following PD-1 blockade in HNSCC.
METHODS: Clinical and immunohistochemical data from 78 patients with recurrent or metastatic HNSCC treated with nivolumab or pembrolizumab were retrospectively analyzed. Expression of PD-L1, LAG-3, TIM-3, and IDO1 on tumor-infiltrating immune cells was assessed. A composite immune checkpoint phenotype was defined by concurrent immune-cell expression of these markers. Associations with treatment response and survival were analyzed.
RESULTS: The composite immune checkpoint phenotype was observed in 10.1% of tumors and was strongly associated with objective response (p < 0.001), disease control (p = 0.006), and improved overall, disease-specific, and progression-free survival (all p ≤ 0.030). In multivariable analysis, this phenotype independently predicted overall (p = 0.031) and disease-specific survival (p = 0.011).
CONCLUSION: Coordinated expression of multiple inhibitory immune checkpoints identifies an inflamed tumor microenvironment associated with improved outcomes following PD-1 blockade in HNSCC.